ImmunologybioRxivPreprint
A first-in-kind MAPK13 inhibitor corrects stem cell reprogramming and muco-obstructive lung disease
Yong Zhang, Kangyun Wu, Dailing Mao…·Michael J. Holtzman
The paper identifies a first-in-kind MAPK13 inhibitor that corrects stem cell reprogramming and reduces muco-obstructive lung disease symptoms in mice.
3 citations